FreeTheAI

Palvella Therapeutics Shares Gain Following Phase 3 QTORIN Rapamycin Data Update

BullishMedium impact
PVLA$138.77 5.66%

Palvella Therapeutics, Inc. (PVLA) reported findings from Phase 3 SELVA trial patient interviews evaluating QTORIN rapamycin. In the study, 95% of participants demonstrated improvement on the mLM-IGA scale at 24 weeks, and 98% chose to enroll in the extension phase. Pharmacokinetic data showed that topical QTORIN rapamycin resulted in at least 40-fold lower systemic exposure than oral sirolimus. Additionally, a health claims analysis estimated that 154,986 patients in the United States are currently diagnosed with disseminated superficial actinic porokeratosis. Shares of the company rose 5.66% to $138.80 following the news.

The trial results highlight patient satisfaction and a reduced systemic exposure profile compared with oral treatments. With a New Drug Application already submitted, Palvella is transitioning from clinical development toward potential regulatory clearance. The patient claims data also helps define the potential target market size for the company's secondary pipeline candidate, QTORIN pitavastatin, ahead of Phase 2 studies.

Investors will monitor progress surrounding the New Drug Application review for QTORIN rapamycin. Key upcoming factors include regulatory milestones and updates regarding Phase 2 development for Palvella's second pipeline candidate.

Key points

  • In Phase 3 SELVA interviews, 95% of participants improved on the mLM-IGA scale at 24 weeks, with 98% entering the extension phase.
  • Topical QTORIN rapamycin demonstrated at least 40-fold lower systemic exposure compared with oral sirolimus.
  • Palvella Therapeutics has submitted a New Drug Application for QTORIN rapamycin, putting regulatory review underway.
  • A U.S. claims analysis identified 154,986 diagnosed DSAP patients ahead of Phase 2 trials for QTORIN pitavastatin.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the key Phase 3 trial results for QTORIN rapamycin?

In Phase 3 SELVA patient interviews, 95% of participants improved on the mLM-IGA scale at 24 weeks, and 98% opted into the extension phase. Systemic exposure was at least 40-fold lower than oral sirolimus.

What is the regulatory status of QTORIN rapamycin?

Palvella Therapeutics has submitted a New Drug Application for QTORIN rapamycin, and regulatory review is currently underway.

How large is the diagnosed DSAP patient market in the United States?

A health claims analysis estimated that 154,986 patients in the U.S. are diagnosed with disseminated superficial actinic porokeratosis.